As U.S. drug shortages run rampant, lawmakers are getting creative with their attempts to ease the situation. | Under the ...

In about a year after launching a revamp strategy under CEO Richard Francis, Teva has managed to return its generics business ...

In a letter to FDA Commissioner Robert Califf, M.D., the House Committee on Oversight and Accountability chairman argued that China’s influence over global pharmaceutical supply chains constitutes an ...

Once hailed as a landmark accomplishment for the speed with which it was developed and a shining example of British innovation, the AstraZeneca coronavirus vaccine has been grounded by the European ...

After Orchard Therapeutics’ gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D. “Every time we ...

Apellis’ geographic atrophy drug Syfovre delivered what CEO Cedric Francois called “robust” growth in the first quarter, as its sales topped analysts’ expectations. | Apellis’ geographic atrophy drug ...

Ennogen, a U.K.-based drug and device maker, reeled in a £30 million ($37.5 million) credit facility that the company will use to expand its international horizons. Santander U.K. is behind the loan ...

After bringing slow-release schizophrenia drug Uzedy to market last year, Teva and France’s MedinCell are using the same playbook for a similar candidate. | The companies second go at a long-acting ...

Otsuka and Lundbeck’s atypical antipsychotic Rexulti has taken the crown away from AbbVie as the largest TV drug ad spender in April, according to the latest data out from real-time ad trackers ...

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the ...

In an ongoing battle for dominance in the eyes of healthcare professionals for their work developing heart disease-focused drugs, Novartis has now snatched the top spot from Pfizer, according to a ...

Even after consumer outfit Kenvue split from Johnson & Johnson one year ago, the company has been performing certain services for the pharma and medtech giant as part of a transition process. | Kenvue ...